
Additional reports of patients with long COVID who were helped by Pfizer Inc's (NYSE:PFE) oral antiviral treatment Paxlovid have surfaced, providing momentum for conducting clinical trials to test the treatment, Reuters wrote.
Three new case studies follow earlier reports of long COVID patients who experienced relief of their symptoms after taking Paxlovid.